Antifungal properties of the anti-hypertensive drug: aliskiren.

Arch Oral Biol

DST-FIST and UGC-SAP Sponsored School of Life Sciences, SRTM University, Nanded, Maharashtra State, India.

Published: September 2013

Objectives: Aliskiren, the first in a new class of orally active renin inhibitors, is licensed for the treatment of hypertension. It inhibits plasma renin activity directly, thereby reducing generation of angiotensin II. In this study, we have explored the anti-Candida properties of aliskiren.

Methods: Candida albicans was cultured in the presence or absence of aliskiren for various time periods. Subsequently, inhibition of growth, germtube formation, adhesion, early/matured biofilm development and secreted aspartic protease (SAP) activity were studied.

Results: When cultured in the presence of aliskiren, Candida showed significant reduction in the activity of aspartic proteases. Aliskiren impaired in vitro growth of C. albicans. It also affected two other virulence factors, germtube and adhesion. There is reduction in early and matured biofilm when treated with aliskiren.

Conclusions: Aliskiren could be considered as a candidate for antifungal drug development.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.archoralbio.2013.02.006DOI Listing

Publication Analysis

Top Keywords

cultured presence
8
aliskiren
6
antifungal properties
4
properties anti-hypertensive
4
anti-hypertensive drug
4
drug aliskiren
4
aliskiren objectives
4
objectives aliskiren
4
aliskiren class
4
class orally
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!